Development and Validation of a Zebrafish Model for Vanishing White Matter Disease
Development and Validation of a Zebrafish Model for Vanishing White Matter Disease
批准号:
10532469
负责人:
Josh Leitch Bonkowsky
金额:
$37.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-12-15 至 2023-11-30
关键词:
AddressAdultAffectAllelesAnimalsAstrocytesAxonBehaviorBiochemicalBiological AssayCRISPR/Cas technologyCessation of lifeClustered Regularly Interspaced Short Palindromic RepeatsDataDemyelinationsDevelopmentDiseaseDisease ProgressionDrug ScreeningEIF2B2 geneEukaryotic Initiation FactorsExonsFertilizationFunctional disorderFutureGenerationsGenesGeneticGenomicsGenotypeGerm CellsGlycineGrowthGuanine Nucleotide Exchange FactorsHepaticHumanImmunohistochemistryImpairmentInheritedInternationalKidneyKnock-inKnock-outLinkLive BirthMagnetic Resonance ImagingMammalsModelingMolecularMolecular DiseaseMotorMutagenesisMutationMyelinNoiseOligodendrogliaPathologyPatientsPediatric HospitalsPhasePhenotypeProductionProteinsRNARNA SplicingReagentReporterResearchSignal TransductionSiteStainsSwimmingSystemTechniquesTestingTherapeuticTranscriptUniversitiesUtahValidationWhite Matter DiseaseWorkZebrafishbehavior testclinical centercostdisabilitydisease phenotypedrug discoveryexperiencegene conservationgenomic RNAin vivoleukodystrophymortalitymouse modelmutantmyelin degenerationnervous system disordernovelscreeningtoolvalidation studieswhite matter
中文摘要
项目总结/文摘
英文摘要
Project Summary/Abstract
Vanishing white matter disease (VWMD) is a common inherited leukodystrophy affecting almost ~1:15,000
live births. VWMD imposes tremendous and often lethal burdens on patients. New treatments are needed.
Our objective is to generate and validate a novel small vertebrate model (zebrafish) for vanishing white
matter disease (VWMD). Mutations in five different subunits of the eukaryotic initiation factor EIF2B (1-5) are
known to cause VWMD, but discovery of treatments for VWMD has been limited by slow disease progression
in mouse models, difficulty in large-scale screening, and high costs. Zebrafish (Danio rerio) offers key
benefits to circumvent these issues: myelin development begins in the first 3 days after fertilization; there is
conservation of genes for myelin development; and low costs and small size facilitate screening not possible
in other systems. We have four specific aims for the R21 and R33 phases of this project. In the R21 phase
we will first, generate zebrafish mutants for vanishing white matter disease, using CRISPR/Cas9
targeting of exons 1 and 2 of eif2B5, and obtaining an eif2B2 splice-site mutant. Second, we will validate
zebrafish VWMD molecular and biochemical phenotypes. We will perform immunohistochemistry for
myelin, oligodendrocytes, and axonal integrity; assays of larval motor (swimming) behavior; and survival
curves. For progression to the R33 phase, Go/No-Go milestones will be the generation and raising of
mutants in eif2B2 and eif2B5; demonstration with PCR and sequencing of the genomic mutations; that RNA
transcript and protein product are lost or diminished; that oligodendrocyte and myelin development is
impaired; and that survival and motor ability are affected. In the R33 phase we will first, characterize
zebrafish VWMD mutant phenotypes compared to human VWMD. We will test whether the zebrafish
mutants have hallmark features of human VWMD, including increased mortality; inducible myelin loss; myelin
changes on MRI; impaired somatic growth; and increased CSF glycine levels. Next, we will test whether
zebrafish VWMD disease pathology is rescued by expression of the human gene, demonstrating
conservation of the genetic and biochemical pathophysiology. Second, we will determine zebrafish VWMD
phenotype range and disease and scale parameters. We will examine ability to generate sufficient
numbers of animals for drug screening. We will test whether swimming behavior or a fluorescent-myelin GFP
reporter in the mutants could be used for screening, and determine the signal-to-noise ratio; throughput
capacity for screening; and expected effect size in comparison to a genetic rescue. In summary, the work
described in this proposal will establish and validate a small vertebrate model for VWMD. This work is
carried out in vivo and utilizes state-of-the-art techniques. This proposal addresses a significant unmet need,
uses unique reagents, and offers significant potential for a therapeutics screening pipeline.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Systems for rapid generation of zebrafish mutants and zebrafish embryo handling
-
批准号:9909292
-
项目类别:
-
资助金额:$21.99万
-
财政年份:2020
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials (UR-NEXT)
-
批准号:10744970
-
项目类别:
-
资助金额:$42.31万
-
财政年份:2018
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Mechanisms of Serotonergic Regulation for Connectivity Development
-
批准号:8889940
-
项目类别:
-
资助金额:$22.35万
-
财政年份:2015
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Trans-Cellular Activation of Transcription to Analyze Dopaminergic Axon Reorganiz
-
批准号:8352193
-
项目类别:
-
资助金额:$223.61万
-
财政年份:2012
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
-
批准号:8709000
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2011
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Characterization and Genetic Analysis of Basal Ganglia Axon Pathfinding
-
批准号:8242817
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2008
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Characterization and Genetic Analysis of Basal Ganglia Axon Pathfinding
-
批准号:8033757
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2008
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Characterization and Genetic Analysis of Basal Ganglia Axon Pathfinding
-
批准号:8618252
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2008
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Characterization and Genetic Analysis of Basal Ganglia Axon Pathfinding
-
批准号:7449190
-
项目类别:
-
资助金额:$18.58万
-
财政年份:2008
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
Characterization and Genetic Analysis of Basal Ganglia Axon Pathfinding
-
批准号:7588745
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2008
-
负责人:Josh Leitch Bonkowsky
-
依托单位:
海外基金